Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 17/20 | 0.64 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19611476 | 1.00 | FOLH1 (0.64) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL19611479 | 1.00 | FOLH1 (0.64) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL17246764 | 0.94 | FOLH1 (0.64) | FOLH1RIMKLANAALAD2 | |
| Trifluoroacetic Acid SCHEMBL19611495 | 0.94 | FOLH1 (0.57) | FOLH1RIMKLANAALAD2 | |
| Trifluoroacetic Acid SCHEMBL19611496 | 0.94 | FOLH1 (0.57) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL19633812 | 0.86 | FOLH1 (0.66) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL27098180 | 0.80 | FOLH1 (0.66) | FOLH1 | |
| SCHEMBL21162263 | 0.80 | FOLH1 (0.66) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL19633801 | 0.79 | FOLH1 (0.57) | FOLH1 | |
| SCHEMBL2450656 | 0.79 | FOLH1 (1.00) | FOLH1RIMKLANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSTY | 2020-11-19 | — | — | US | disclosed |
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSTY | 2020-11-19 | — | — | US | disclosed |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | FOLH1 1/4885RIMKLA 155/4885NAALAD2 189/4885 |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | FOLH1 1/4885RIMKLA 155/4885NAALAD2 189/4885 |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | FOLH1 1/4885RIMKLA 127/4885NAALAD2 163/4885 |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | FOLH1 1/4885RIMKLA 155/4885NAALAD2 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.